Revolution Medicines (NASDAQ: RVMD) 30-day option implied volatility is at 58; compared to its 52-week range of 40 to 125. Call put ratio 3.3 calls to 1 put after the company presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO.